RxDoctor Payments Data

Jeff Pro, MD

Internal Medicine · State College, PANPI 1114980208

Payments from drug & device makers

$1,467in general payments, 2019–2025

Across 84 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556
  • Pfizer$313
  • Novo Nordisk$164
  • GSK$76
  • E.r. Squibb & Sons, L.L.C.$74
  • Lilly USA, LLC$63
  • plus $220 from 9 others

What the payments were for

  • Food & beverage$1,467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,467 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$119,923
Medicare patients
341
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$220,258
OzempicSemaglutide58$79,671
TrulicityDulaglutide53$71,205
MounjaroTirzepatide51$58,270
XareltoRivaroxaban40$55,865
JardianceEmpagliflozin31$27,985
MyrbetriqMirabegron31$16,967
LinzessLinaclotide21$14,055
NeuproRotigotine13$10,471
Atorvastatin Calcium671$9,263
Levothyroxine Sodium780$9,019
FarxigaDapagliflozin Propanediol11$8,598
Breo ElliptaFluticasone/Vilanterol14$8,070
Metoprolol Succinate305$7,142
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$5,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$313$220,258242 claims
Lilly USA, LLCTrulicity, Mounjaro$63$129,475104 claims
Novo NordiskOzempic$164$79,67158 claims
Johnson & JohnsonXarelto$30$55,86540 claims
Boehringer IngelheimJardiance$13$27,98531 claims
AbbVieLinzess, Synthroid$556$19,644142 claims
GSKBreo Ellipta$76$8,07014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →